AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00946205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior mesh rectopexy
Description: The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
Study NCT01712295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17% Salicylate with ethyl pyruvate
Study NCT01712295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salicylates
Study NCT02046447 — intervention group
Intervention type: DRUG
Intervention: Primary Cervical Dystonia (Trihexyphenidyl)
Description: After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
Study NCT02046447 — intervention group
Intervention type: OTHER
Intervention: Controls Primary Cervical Dystonia (Trihexyphenidyl)
Description: These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
Study NCT02046447 — intervention group
Intervention type: OTHER
Intervention: DYT 1 Dystonia (Healthy Control)
Description: These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
Study NCT02046447 — intervention group
Intervention type: OTHER
Intervention: DYT 1 Dystonia
Description: These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
Study NCT00907946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NT 1 day before PCNL
Description: A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~1. Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~2. If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol.
Study NCT04561167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cuspal reduction in MOD cavity in endodontically treated teeth
Description: Not only the quality of endodontic treatment that affects the prognosis of the endodontically treated tooth, but the subsequent restorative treatment as well. Coverage, Endocrowns, Onlays, Inlays Restorations on Fracture Resistance of Endodontically Treated Molars, it was found that the worst results came to the inlay restorations and this was attributed to geometric form of preparation that exert a wedging force acting to split the tooth when under occlual stress however, onlay and full coverage direct the force along the long axis by overlaying the cusp tips and a portion of buccal and lingual surface thus opposing the wedging action created by internal design of restoration (Magne P and Belser C. et al 2003) That's why, choosing such a design as a comparator to the design of the cuspal reduction and further coverage (onlay) is crucial to show the importance of cuspal coverage for the indirect resin composite restoration in the endodontically treated teeth.
Study NCT04561167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No cuspal reduction in MOD cavity in endodontically treated teeth
Description: In an invitro study done by (Ahmed Hamdy 2015) investigating the effect of Full The amount of lost internal tooth structure as well as the coronal hard tissue in an endodontically treated tooth is considered the main factors that make the tooth susceptible to biomechanical failure when compared to a vital tooth. (Guo J et al 2016) .
Study NCT01157377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into the bladder.
Study NCT01157377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-214868 placebo
Description: AGN-214868 placebo injected into the bladder.
Study NCT03289806 — intervention group
Intervention type: PROCEDURE
Intervention: Samples of fibroblasts from Tenon's capsule
Study NCT00372255 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influsplit SSW® 2005/2006
Description: Study influenza vaccine was administered intramuscularly in the non-dominant arm
Study NCT00372255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit SSW® 2005/2006
Description: Study influenza vaccine was administered intramuscularly in the non-dominant arm
Study NCT00958607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Timing it Right Stroke Family Support Person Intervention
Description: Intervention delivered by a stroke support person (SSP) in-person during acute care \& by telephone during inpatient rehabilitation and community discharge. SSP provides support, information \& guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
Study NCT01309113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VAC BNO 1095 film coated tablets
Description: 3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
Study NCT01309113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VAC BNO 1095 film coated tablets
Description: 3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
Study NCT02856061 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pivotal Response Treatment
Description: Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
Study NCT00958607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed program
Description: Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
Study NCT01900431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab
Description: Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
Study NCT01900431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
Study NCT01900431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Study NCT01900431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Study NCT01900431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
Study NCT01900431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
Study NCT01900431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic/folinic acid
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Study NCT01900431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic/folinic acid
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Study NCT01900431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Sarilumab)
Description: Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
Study NCT02467894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based Care
Description: There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
Study NCT02539134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution
Study NCT03697083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminders Through Association
Description: Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.
Study NCT03697083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.
Study NCT03697083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Control
Description: Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
Study NCT02539134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-935 placebo-matching oral solution
Study NCT01290783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irintoecan
Description: * Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment.
Study NCT01290783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA-Irinotecan solution for Infusion
Description: * HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks~* 8 months of treatment.
Study NCT00741351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane + Fentanyl
Description: Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
Study NCT00741351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane + Remifentanyl
Description: Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
Study NCT00741351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol + Remifentanyl
Description: Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
Study NCT02640222 — intervention group
Intervention type: DRUG
Intervention: VKA
Study NCT02640222 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Study NCT02640222 — intervention group
Intervention type: DRUG
Intervention: dabigatran
Study NCT02640222 — intervention group
Intervention type: DRUG
Intervention: rivaroxaban
Study NCT03212950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-CL
Description: After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
Study NCT03212950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular-CL
Description: After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
Study NCT02692287 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The PPH Butterfly
Description: The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
Study NCT02786290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenflow Spring System
Description: The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
Study NCT03553485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation
Description: The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.
Study NCT03553485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.
Study NCT03553485 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiotherapy
Description: Standard treatment for included patients
Study NCT03553485 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard treatment for included patients
Study NCT05202275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx, 69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5 at every chemotherapy cycle.
Study NCT00396877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel (SR25990)
Description: Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Study NCT00396877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Study NCT04060199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viltolarsen
Description: IV infusion
Study NCT04060199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT03738449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: Test drug
Study NCT03738449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: reference drug
Study NCT02259634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Motivational Interviewing
Study NCT01093651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg sitagliptin daily for 4-6 months
Study NCT01093651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo for 4-6 months
Study NCT01752868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
Study NCT00376272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Study NCT00376272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02984267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Using ultrasound guidance to evaluate the spine prior to epidural placement
Study NCT04402203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
Study NCT04402203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Only Standard Treatment
Description: Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
Study NCT02496143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.